Clinical trial
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian…
NCT00052065 · Telik, Industry · Completed
Key facts
| NCT number | NCT00052065 |
|---|---|
| Title | TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer |
| Official title | Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer |
| Lead sponsor | Telik, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | TLK286 |
| Enrollment | 28 |
| Start date | Feb 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Jan 23, 2003 |
| Last update posted | Jul 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: